Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EBT (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBT for 2 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 194.7% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.4 million, a N/A change, with the full-year FY2025 number at -$7.1 million, up 48.32% from a year prior.
  • EBT was $1.8 million for Q4 2025 at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $11.2 million in Q1 2025 to a low of -$15.4 million in Q2 2025.